Evidence map›Paper›PMID 37308559›Full record

ArticleCellular & molecular immunology2023

A subpopulation of CD146

Lin Jing, Yunhe An, Tanxi Cai, Jianquan Xiang, Baoming Li, Jiang Guo, Xinran Ma, Ling Wei, Yanjie Tian, Xiaoyan Cheng and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. The double-positive cells in the tumor microenvironment.Journal of translational internal medicine · 2026
    Article
  8. Review
  9. Review
  10. Journal for immunotherapy of cancer · 2025
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Lin Jing *Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Yunhe An *Institute of Analysis and Testing, Beijing Academy of Science and Technology (Beijing Center for Physical and Chemical Analysis), No. 7 Fengxian Middle Street, Haidian District, Beijing, 100094, China.
Tanxi Cai *Sino-Danish College, University of Chinese Academy of Sciences, Beijing, 100049, China.
Jianquan XiangKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Baoming LiInstitute of Analysis and Testing, Beijing Academy of Science and Technology (Beijing Center for Physical and Chemical Analysis), No. 7 Fengxian Middle Street, Haidian District, Beijing, 100094, China.
Jiang GuoDepartment of Interventional Oncology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Xinran MaKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Ling WeiInstitute of Analysis and Testing, Beijing Academy of Science and Technology (Beijing Center for Physical and Chemical Analysis), No. 7 Fengxian Middle Street, Haidian District, Beijing, 100094, China.
Yanjie TianInstitute of Analysis and Testing, Beijing Academy of Science and Technology (Beijing Center for Physical and Chemical Analysis), No. 7 Fengxian Middle Street, Haidian District, Beijing, 100094, China.
Xiaoyan ChengInstitute of Analysis and Testing, Beijing Academy of Science and Technology (Beijing Center for Physical and Chemical Analysis), No. 7 Fengxian Middle Street, Haidian District, Beijing, 100094, China.
Xuehui ChenKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Zheng LiuKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Jing FengKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Fuquan YangKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. fqyang@ibp.ac.cn.
Xiyun YanKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. yanxy@ibp.ac.cn.ORCID http://orcid.org/0000-0002-7290-352X
Hongxia DuanKey Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. cherryshoen@ibp.ac.cn.ORCID http://orcid.org/0000-0003-3995-1228
Chinese Academy of Sciences · CNBeijing Academy of Science and Technology · CNCapital Medical University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the main tumor-infiltrating immune cell types, tumor-associated macrophages (TAMs) determine the efficacy of immunotherapy. However, limited knowledge about their phenotypically and functionally heterogeneous nature restricts their application in tumor immunotherapy. In this study, we identified a subpopulation of CD146

Indexed as

InflammasomesNeoplasmsAnimalsCD146 AntigenHumansMacrophagesNLR Family, Pyrin Domain-Containing 3 ProteinTumor MicroenvironmentCD146 AntigenInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinCD146InflammasomeTMEM176BTumor-associated macrophagesTumor immunotherapy

Identifiers

PMID37308559
PMCPMC10387481
OpenAlexW4380369723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.